PDBsum entry 4x6n

Hydrolase/hydrolase inhibitor

PDB id: 4x6n

Contents

Protein chain

238 a.a.

Ligands

CYS-THR-THR-LYS-ILE-LYS-PRO

3Y5

SO4

EDO ×11

Waters ×177

PDB id:

4x6n

Name:

Hydrolase/hydrolase inhibitor

Title:

Factor xia in complex with the inhibitor 1-{(1s)-1-[4-(3-amino-1h- indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl}-3-[5-chloro- 2-(1h-tetrazol-1-yl)benzyl]urea

Structure:

Coagulation factor xi, light chain. Chain: a. Synonym: fxi,plasma thromboplastin antecedent,pta. Engineered: yes. Mutation: yes. Cleaved peptide. Chain: h. Engineered: yes

Source:

Homo sapiens. Human. Organism_taxid: 9606. Gene: f11. Expressed in: escherichia coli. Expression_system_taxid: 562.

Resolution:

2.10Å R-factor: 0.175 R-free: 0.210

Authors:

A.Wei

Key ref:

D.J.Pinto et al. (2015). Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties. Bioorg Med Chem Lett, 25, 1635-1642. PubMed id: 25728130 DOI: 10.1016/j.bmcl.2015.01.028

Date:

08-Dec-14 Release date: 18-Feb-15

Protein chain

P03951  (FA11_HUMAN) -  Coagulation factor XI from Homo sapiens

Seq: 625 a.a.

Struc: 238 a.a.*

* PDB and UniProt seqs differ at 2 residue positions (black crosses)

Enzyme reactions

• Enzyme class: E.C.3.4.21.27 - coagulation factor XIa.
• Reaction: Selective cleavage of Arg-|-Ala and Arg-|-Val bonds in factor IX to form factor IXa.

DOI no: 10.1016/j.bmcl.2015.01.028

Bioorg Med Chem Lett 25:1635-1642 (2015)

PubMed id: 25728130

Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.

D.J.Pinto, J.M.Smallheer, J.R.Corte, E.J.Austin, C.Wang, T.Fang, L.M.Smith, K.A.Rossi, A.R.Rendina, J.M.Bozarth, G.Zhang, A.Wei, V.Ramamurthy, S.Sheriff, J.E.Myers, P.E.Morin, J.M.Luettgen, D.A.Seiffert, M.L.Quan, R.R.Wexler.

ABSTRACT

Compound 2 was previously identified as a potent inhibitor of factor XIa lacking oral bioavailability. A structure-based approach was used to design analogs of 2 with novel P1 moieties with good selectivity profiles and oral bioavailability. Further optimization of the P1 group led to the identification of a 4-chlorophenyltetrazole P1 analog, which when combined with further modifications to the linker and P2' group provided compound 32 with FXIa Ki=6.7nM and modest oral exposure in dogs.